Evaluation of L/N type Ca2+ channel blocker (cilnidipine) in hypertension complicated diabetes or sleep apnea syndrome ; Trial for the effects of improvementof arteriosclerosis and renal function.
Not Applicable
Recruiting
- Conditions
- Diabetes/Hypertension/Sleep apnea syndrome
- Registration Number
- JPRN-UMIN000014635
- Lead Sponsor
- Kanazawa Medical Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with Ca blocker taking. 2) Pregnancy, or patients who are its possible. 3) Patients with a history of hypersensitivity to Ca blocker. 4) Patients the physician judged inappropriate to this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method office blood presure PWV IMT urinary albumin (diabetes only) urinary LFAB-P
- Secondary Outcome Measures
Name Time Method e-GFR adiponectin hs-CRP